Our CBD 5% + CBG 5% drops with MCT oil work either day or night to restore balance in your body. Made with pure CBD and CBG extracted from the hemp plant and blended with organic MCT oil. 100% natural, vegan, GMO-free and cruelty-free.
- 500mg infused CBG content + 500mg ultra-pure CBD isolate
- Made from 100% natural EU hemp
- Laboratory-tested for purity and cannabidiol & cannabigerol content
- Manufactured and bottled in Consett, UK
||500 mg + 500mg|
|Ingredients||Prepared from 97,25% CBG Isolate (THC free) Contents CBG 5% (520mg isolate) and 100% CBD isolate (THC free) Contents CBD 5% 500mg: all in MCT oil|
|Usage instruction||2 drops under the tongue twice daily. See Dosage tab for more details|
Every person is different, so your dosage is dependent on your requirements. Listen carefully to your body and build the dosage slowly. Our product is pleasant tasting and colourless. The taste is neutral.
Typical dosage of this high concentration CBD/CBG oil: 2 drops under the tongue twice daily. Do not exceed 8 drops per day. Leave four hours before taking any other medicine.
If you are pregnant or breastfeeding, we recommend that you do not use any CBD or CBG products.
If you have a medical condition or if you are on medication, always consult with your doctor before you start using CBD or CBG. If you have any allergies, please read the ingredients list carefully.
Both CBD and CBG have been found to display therapeutic effects in Inflammatory Bowel Disease:
Crohn’s Disease (Inflammatory Bowel Disease) can not be treated yet, but some pre-clinical studies conducted on mice in 2013 suggest that CBG seems to reduce the inflammation(4). Additionally, CBD is able to modulate the immune response to gut inflammation as described in a 2011 study(8). CBD and CBG are therefore regarded as a promising therapeutic agents in the treatment of inflammatory bowel disorders.
The CBG studies require more research, but some benefits have already been found in treatment of the following conditions:
- Glaucoma - According to a study published in 2008(1) CBG reduces intraocular pressure and therefore it might be effective in treating Glaucoma
- Bladder Dysfunction Aid - CBG was the most effective in the inhibition of muscle contractions inside the human bladder(2) according to study from 2015
- Bacterial infections - Another study from 2008 shows that CBG may combat Staphylococcus aureus (MRSA)(3), a particularly resistant superbug bacteria
- Loss of appetite - CBG can work as an appetite stimulant(5)
Here’s what the research says about using CBD
- Epilepsy - Human trials completed in relation to epilepsy(6) have shown no seizures in patients who were taking the CBD
- Nausea - CBD may be effective at reducing symptoms of nausea (based on rats and shrews studies from 2020)(7)
- Anxiety and insomnia - CBD is also commonly used to address anxiety, and insomnia. Some studies suggest that CBD may help with both falling asleep and staying asleep(9)
- Chronic pain - A study from 2018(10) examined the use of CBD among other medicines and found they might be of some benefit in the treatment of chronic neuropathic pain and inflammation due to arthritis.
(1) Krystyna Nadolska, Roman Goś, "Possibilities of applying cannabinoids' in the treatment of glaucoma", Published 2008, Medicine, Klinika oczna
(2) Ester Pagano, Vittorino Montanaro, Antonio Di Girolamo, Antonio Pistone, Vincenzo Altieri, Jordan K Zjawiony, Angelo A Izzo, Raffaele Capasso, "Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol", Published June 1, 2015, Natural Product Communications
(3) Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith, and M. Mukhlesur Rahman, Antibacterial cannabinoids from Cannabis sativa: a structure-activity study, Published August 6, 2008, The American Chemical Society and American Society of Pharmacognosy
(4) Francesca Borrelli, Ines Fasolino, Barbara Romano, Raffaele Capasso, Francesco Maiello, Diana Coppola, Pierangelo Orlando, Giovanni Battista, Ester Pagano, Vincenzo Di Marzo, Angelo A Izzo "Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease", Published May 1, 2013, Biochemical pharmacology
(5) Daniel I Brierley, James Samuels, Marnie Duncan, Benjamin J Whalley, Claire M Williams, "Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats", Published in October 2016, Psychopharmacology
(6) J M Cunha, E A Carlini, A E Pereira, O L Ramos, C Pimentel, R Gagliardi, W L Sanvito, N Lander, R Mechoulam "Chronic Administration of cannabidiol to healthy volunteers and epileptic patients", Published in February 1980, Pharmacology
(7) Erin M Rock, Megan T Sullivan, Stephen A Collins, Hannah Goodman, Cheryl L Limebeer, Raphael Mechoulam, Linda A Parker, "Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews", Published June 2, 2020, Psychopharmacology
(8) Daniele De Filippis, Giuseppe Esposito, Carla Cirillo, Mariateresa Cipriano, Benedicte Y De Winter, Caterina Scuderi, Giovanni Sarnelli, Rosario Cuomo, Luca Steardo, Joris G De Man, Teresa Iuvone, "Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis", Published December 2011, PLoS ONE
(9) Scott Shannon, Nicole Lewis, Heather Lee, Shannon Hughes, "Cannabidiol in Anxiety and Sleep: A Large Case Series", Published January 7, 2019, The Permanente Journal
(10) Martin Mücke, Tudor Phillips, Lukas Radbruch, Frank Petzke, Winfried Häuser, "Cannabis‐based medicines for chronic neuropathic pain in adults", Published March 7, 2018, Cochrane database of systematic reviews